Inclisiran vs bempedoic acid for low-density lipoprotein cholesterol lowering in high-risk patients: the VICTORION-Challenge trial

Clicks: 27
ID: 327109
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #68 of 374 articles by views in european heart journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 374 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND AND AIMS: Low-density lipoprotein cholesterol (LDL-C) targets remain unmet in many high-risk atherosclerotic cardiovascular disease (ASCVD) patients on statins (± ezetimibe). VICTORION-Challenge compared inclisiran with bempedoic acid (BPA) for LDL-C lowering and target attainment in these patients, directly. METHODS: In this phase 4, open-label study, ASCVD patients with LDL-C ≥70 mg/dL on statins (± ezetimibe) were randomized to inclisiran or BPA. The primary endpoint was percentage change in LDL-C at Day 150; key secondary endpoints at Day 150 included percentage LDL-C change stratified by ezetimibe use. Secondary endpoints included LDL-C goal attainment and absolute change; treatment-emergent adverse events (TEAEs) were evaluated. RESULTS: Among 402 randomized patients (mean±standard deviation age, 63.1±10.7 years; 64.2% men; baseline LDL-C 94.4±28.3 mg/dL), LDL-C reduction at Day 150 was superior with inclisiran vs BPA (least squares mean -56.3% vs -15.4%; between-group difference -41.0%, 95% confidence interval [CI] -45.7 to -36.2; p<0.0001). Inclisiran achieved greater absolute LDL-C reduction at Day 150 (-53.4 vs -17.5 mg/dL) regardless of ezetimibe use, with higher LDL-C goal attainment (78.2% vs 20.3%; adjusted odds ratio 16.36, 95% CI 9.72 to 27.54; descriptive p<0.0001). Inclisiran showed a favourable safety profile vs BPA, with comparable rates of TEAEs (63.1% vs 59.8%) and serious TEAEs (5.9% vs 7.5%). Most common TEAEs (inclisiran vs BPA) included nasopharyngitis (10.3% vs 7.5%), hypertension (4.9% vs 4.5%), and myalgia (3.4% vs 5.5%). One non-treatment-related death (inclisiran) was reported. CONCLUSIONS: Inclisiran provided superior LDL-C reduction versus BPA with favourable safety, supporting its use in high-risk patients not achieving guideline-recommended goals.
Reference Key
openalex_W7204754146 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ingo Hilgendorf, Dirk Westermann, Bernd Nowak, Peter Uebel, Martin Dürsch, Amir A. Mahabadi, Gregor Nagel, Uwe Gerbaulet, S Hiltl, Mirjam Metzner, Margarita Pruckner, Patrick Schwaferts, Jan-Hendrik Streich, Daniel Thieme, Anne Groß-Bsharat, Wolfgang Köenig, Ulf Landmesser
Are you one of these authors? Claim your profile
Journal european heart journal
Year 2026
DOI
10.1093/eurheartj/ehag738
URL
https://academic.oup.com/eurheartj/advance-article-pdf/doi/10.1093/eurheartj/ehag738/70852669/ehag738.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.